Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 5/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.34 |
| ▸ | IKBKB | O14920 | 1/20 | 0.30 |
| ▸ | CHUK | O15111 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21752742 | 0.82 | CSNK2A1 (0.38) | CSNK2A1TNFRIPK1GPR84AHR | |
| SCHEMBL2535930 | 0.78 | GPR84 (0.50) | TNFRIPK1GPR84AHRCYP2A6 | |
| SCHEMBL30950714 | 0.78 | GPR84 (0.45) | CSNK2A1TNFRIPK1GPR84AHR | |
| SCHEMBL621046 | 0.77 | PTPRC (0.43) | CSNK2A1TNFRIPK1IKBKBCHUK | |
| SCHEMBL148870 | 0.77 | TNF (0.48) | CSNK2A1TNFRIPK1GPR84AHR | |
| SCHEMBL29506982 | 0.77 | TNF (0.48) | CSNK2A1TNFRIPK1GPR84AHR | |
| SCHEMBL1137858 | 0.77 | AHR (0.47) | CSNK2A1TNFRIPK1GPR84AHR | |
| SCHEMBL622205 | 0.76 | IKBKB (0.42) | CSNK2A1RIPK1IKBKBCHUK | |
| SCHEMBL1741436 | 0.75 | TNF (0.38) | TNFRIPK1GPR84AHRIKBKB | |
| SCHEMBL18876057 | 0.75 | TNF (0.38) | TNFRIPK1GPR84AHRIKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435128-B2 | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-10-07 | — | — | US | disclosed |
| US-12018033-B2 | Inhibitors of protein arginine deiminases | FORWARD THERAPEUTICS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| EP-3702354-B1 | COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF | HAIHE BIOPHARMA CO LTD (CN) | 2024-05-22 | — | — | EP | disclosed |
| CN-110740991-B | Novel biphenyl compound or salt thereof | 大鹏药品工业株式会社 | 2023-07-04 | — | — | CN | disclosed |
| EP-3632443-B1 | ANTI-TUMOR EFFECT POTENTIATOR USING A BIPHENYL COMPOUND | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-06-07 | — | — | EP | disclosed |
| EP-3381896-B1 | BIPHENYL COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-01-18 | — | — | EP | disclosed |
| US-11510915-B2 | Anti-tumor effect potentiator using novel biphenyl compound | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2022-11-29 | — | — | US | disclosed |
| US-11479563-B2 | Biphenyl compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2022-10-25 | — | — | US | disclosed |
| US-11465984-B2 | Compound having ERK kinase inhibitory activity and use thereof | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) | 2022-10-11 | — | — | US | disclosed |
| CN-108602770-B | Novel biphenyl compound or salt thereof | 大鹏药品工业株式会社 | 2022-02-08 | — | — | CN | disclosed |
| EP-3633380-A1 | METHOD FOR PREDICTING THERAPEUTIC EFFECT OF LSD1 INHIBITOR BASED ON EXPRESSION OF INSM1 | Taiho Pharmaceutical Co., Ltd. (JP) | 2020-04-08 | — | — | EP | disclosed |
| CN-110740991-A | Novel biphenyl compound or salt thereof | 大鹏药品工业株式会社 | 2020-01-31 | — | — | CN | disclosed |
| WO-2019062949-A1 | COMPOUND HAVING ERK KINASE INHIBITORY ACTIVITY AND USE THEREOF | 上海海和药物研究开发有限公司 | 2019-04-04 | — | — | WO | disclosed |
| US-20180354960-A1 | NOVEL BIPHENYL COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-12-13 | — | — | US | disclosed |
| EP-3381896-A1 | NOVEL BIPHENYL COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2018-10-03 | — | — | EP | disclosed |
| EP-3209654-B1 | NEW PYRAZOLE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-10-03 | — | — | EP | disclosed |
| US-9981962-B2 | Pyrazole derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-29 | — | — | US | disclosed |
| US-20170334900-A1 | NEW PYRAZOLE DERIVATIVES AS NIK INHIBITORS | ARGENTA DISCOVERY 2009 LIMITED (GB) | 2017-11-23 | — | — | US | disclosed |
| US-20120245344-A1 | GPR119 AGONIST | NIPPON CHEMIPHAR CO., LTD. (JP) | 2012-09-27 | — | — | US | disclosed |
| EP-2474540-A1 | GPR119 AGONIST | Nippon Chemiphar Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334900-A1 | NEW PYRAZOLE DERIVATIVES AS NIK INHIBITORS | MAP3K14, MAP3K15, MAP3K21 | CSNK2A1 886/4885TNF 153/4885RIPK1 66/4885 |
| US-11465984-B2 | Compound having ERK kinase inhibitory activity and use thereof | MAPK1, MAPK4, MAPK7 | CSNK2A1 182/4885TNF 2166/4885RIPK1 1253/4885 |
| US-11479563-B2 | Biphenyl compound or salt thereof | BMI1, KDM1B, KDM1A | CSNK2A1 692/4885TNF 4192/4885RIPK1 1096/4885 |
| US-12435128-B2 | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 | INMT, CARM1, KDM1B | CSNK2A1 3750/4885TNF 4846/4885RIPK1 528/4885 |
| US-20180354960-A1 | NOVEL BIPHENYL COMPOUND OR SALT THEREOF | KDM1B, HDAC1, DOT1L | CSNK2A1 357/4885TNF 4750/4885RIPK1 974/4885 |
| US-11510915-B2 | Anti-tumor effect potentiator using novel biphenyl compound | KDM1B, KDM1A, DOT1L | CSNK2A1 1622/4885TNF 4558/4885RIPK1 1704/4885 |
| US-20120245344-A1 | GPR119 AGONIST | GPR119, GPR4, GPR55 | CSNK2A1 1945/4885TNF 4498/4885RIPK1 3706/4885 |
| US-12018033-B2 | Inhibitors of protein arginine deiminases | PADI2, PADI1, PADI4 | CSNK2A1 2500/4885TNF 4080/4885RIPK1 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.